The added value of ¹⁸F-FDG PET/CT compared to ⁶⁸Ga-PSMA PET/CT in patients with castration-resistant prostate cancer

Purpose: The 68Ga-PSMA PET/CT is a commonly used imaging modality in prostate cancers. However, few studies have compared the diagnostic efficiency between and 18F-FDG evaluated whether heterogeneous metabolic phenotype (especially PSMA-FDG+ lesions) exists patients with castration-resistant cancer (CRPC). We determined added value of to CRPC identified who may benefit from additional PET/CT. Methods: Data 56 underwent both May 2018 February 2021 were retrospectively analysed. Patients classified into two groups or without lesions. differences patient characteristics predictors having at least one lesion Results: Although detection rate (75.0% vs. 51.8%, P = 0.004) positive number (135 95) higher than PET/CT, there still 13/56 (23.2%) lesion. prostate-specific antigen (PSA) Gleason score lesions those (P 0.04 P<0.001, respectively). Multivariate regression analysis showed that (?8) PSA (?7.9 ng/mL) associated had 0.01 0.04, incidences low-probability (Gleason score<8 PSA<7.9 ng/mL), medium-probability score?8 ng/mL PSA?7.9 high-probability 0%, 21.7%, 61.5%, respectively (P<0.001). Conclusion: are significant for lesions, high